Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class (Oral Contraceptives, Antiandrogens, Insulin-sensitizing Agent, Antidepressant, Anti-obesity), By Surgery, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global polycystic ovarian syndrome treatment market size was estimated at USD 4.79 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030. The growth rate is attributed to lifestyle changes, indulgence in alcohol, rising incidences of depression and stress, and hormonal imbalance.

As of February 2025, the World Health Organization (WHO) estimates that polycystic ovary syndrome (PCOS) affects approximately 6-13% of women of reproductive age globally. Despite its prevalence, up to 70% of affected women remain undiagnosed, underscoring significant gaps in awareness, diagnosis, and access to care.

The prevalence of diabetes is growing in polycystic ovarian syndrome cases. According to the World Health Organization (WHO), women with a type 2 diabetes family history are at a higher risk of polycystic ovarian syndrome. In addition, the Centers for Disease Control and Prevention (CDC) stated that people suffering from the condition are unable to produce insulin, an essential hormone to balance blood sugar, resulting in insulin resistance, leading to type 2 diabetes. Such rising chronic diseases are expected to drive the treatment market growth.

Obesity is another driving factor that causes polycystic ovarian syndrome. According to the World Health Organization (WHO), 2.5 billion adults were overweight in 2022, of which 44% were women. The people affected with this condition were also suffering from obesity, and with weight gain, the PCOS condition developed, as per the endocrine center. The rise in such health conditions and the increase in polycystic ovarian syndrome cases result in market growth.

Recent research from Children's Hospital Colorado indicates that semaglutide, a GLP-1 receptor agonist, may alleviate symptoms of PCOS. Dr. Melanie Cree's studies suggest that semaglutide can improve insulin sensitivity and promote weight loss, which are critical factors in managing PCOS. The RESTORE study is investigating the role of semaglutide, with or without metformin, in restoring ovulation in adolescents and young adults with PCOS. Preliminary findings show that semaglutide may enhance reproductive health outcomes in this population.

Market Concentration & Characteristics

The polycystic ovarian syndrome treatment market demonstrates a high degree of innovation, driven by the growing demand for personalized and holistic care approaches. Traditional treatments, such as oral contraceptives and insulin-sensitizing agents, are being complemented by novel therapies targeting the underlying causes of PCOS. For instance, a groundbreaking study published in 2024 highlighted the potential of artemisinin, an anti-malarial drug, in treating PCOS by inhibiting the enzyme CYP11A1, thereby reducing testosterone production and restoring fertility in women. Additionally, the integration of artificial intelligence (AI) in diagnostics is enhancing early detection and personalized treatment plans.

The polycystic ovarian syndrome treatment market experiences a high level of mergers and acquisitions (M&A), as major players seek to broaden their technological capabilities, enhance their product portfolios, and enter new regional markets. Several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies. In December 2021, Organon acquired Forendo Pharma, a company specializing in clinical-stage drug development for women's health, including a preclinical program focused on PCOS. Furthermore, collaborations between pharmaceutical giants are fostering the development of targeted therapies. For example, a multi-target partnership between Evotec S.E., Bayer AG, and Celmatix Inc. is underway to develop clinical candidates for managing PCOS, leveraging novel therapeutic targets discovered by Celmatix. These strategic alliances are instrumental in accelerating the development and commercialization of innovative treatments for PCOS.

Regulatory frameworks play a pivotal role in shaping the market. Clear guidelines surrounding clinical trials and research are essential for mitigating uncertainties faced by developers. When regulatory bodies provide explicit directives on efficacy and safety requirements, it encourages more research and investment into PCOS treatments. Moreover, the inclusion of real-world evidence in evaluating treatment effectiveness allows for a more comprehensive understanding of patient responses, facilitating the development of tailored therapies.

Product expansion is at a high level in the polycystic ovarian syndrome treatment market. The market encompasses a wide range of treatments, including hormonal drugs, anti-diabetics, anti-obesity drugs, and antidepressants. Recent developments include the introduction of personalized medicine approaches, leveraging genetic and biomarker information to tailor therapies to individual patients. Additionally, the integration of lifestyle modifications with pharmaceutical treatments is becoming increasingly common, offering a holistic approach to managing PCOS symptoms. Companies are also exploring the development of nutraceuticals and natural supplements, catering to the growing consumer preference for plant-based, organic solutions.

The PCOS treatment market is witnessing robust regional expansion, driven by increasing prevalence rates and rising awareness across various geographies, initiatives like SPIOMET4Health aiming to provide comprehensive treatment for PCOS. Asia Pacific is projected to register the fastest growth, fueled by increasing government initiatives to raise awareness about PCOS symptoms and diagnosis. For instance, the Indian Council of Medical Research (ICMR) initiated a nationwide multicentric study in 2021 to address the rising prevalence of PCOS. China is also emerging as a lucrative market, with a large pool of obese female population at high risk of PCOS, presenting tremendous growth opportunities for global and local players.

Drug Class Insights

Insulin-sensitizing agents dominated the market and accounted for a share of 36.0% in 2024. Patients affected by PCOS tend to have diabetes issues due to insulin resistance, leading to type 2 diabetes. The insulin-sensitizing agents regulate the insulin and maintain healthy blood sugar levels. For instance, metformin is a commonly used insulin-sensitizing medicine among patients affected with PCOS to induce ovulation in infertile women. In addition, according to the Frontiers study published in January 2023, resveratrol (RES) was seen to regulate insulin resistance in PCOS patients by improving the glycolytic pathway and providing effective treatment.

Oral contraceptives are expected to register the fastest CAGR over the forecast period. Oral contraceptive pills can be used to mitigate the symptoms of PCOS. The birth-control type used to treat PCOS is combined hormonal birth control pills, as they may regulate menstrual bleeding and reduce excessive hair growth associated with the syndrome. Some oral contraceptive pills used to treat the syndrome are clomiphene combined with metformin and Letrozole to treat the condition and the issue of infertility among women suffering from the syndrome. Some key players producing these contraceptives are Avet Pharmaceuticals Inc., Breckenridge Pharmaceutical, Inc., Seqens, and SUANFARMA.

Surgery Insights

Laparoscopic ovarian drilling accounted for the largest market revenue share of 68.9% in 2024. It is a surgical treatment for PCOS, which can help with ovulation. The surgical alternative is opted when the drug therapy proves ineffective, where the patient cannot ovulate despite weight loss and usage of fertility medicine. The hospitals and clinics performing the surgery are CommonSpirit Health, Ethos Health Care, NEO Fertility Treatment, Mayo Foundation for Medical Education and Research (Mayo Clinic), and Endometriosis Clinic.

Ovarian wedge resection is the second fastest-growing segment, significantly growing during the forecast period. The resection procedure is used to treat PCOS, which may regulate the menstrual cycle and promote ovulation. The post-surgery results saw a significant decrease in testosterone levels, improved insulin levels, and a normal menstrual cycle.

Distribution Channel Insights

The hospital pharmacy segment accounted for the largest market revenue share of 65.0% in 2024. The growing incidences of the syndrome and the demand for oral contraceptives are driving the segment growth. Surgery to treat the syndrome can be performed only at clinics and hospitals; therefore, they have in-house pharmacies to provide the required medical assistance.

Online providers are expected to register the fastest CAGR during the forecast period. Various online portals are available where healthcare professionals can consult patients for treatment. Oral contraceptive orders can be placed in online pharmacies to avoid hesitation among women. Online healthcare portals such as Uvi Health provide online consultations in case of emergencies or severe pain when the patient is unable to visit the clinic or hospital. Some online platforms offering PCOS consultations are Allara Health, TalktoAngel, Practo, and PlushCare. Such technological innovations are driving the segment growth.

Regional Insights

North America polycystic ovarian syndrome treatment market dominated in 2024.  According to a study published by ScienceDirect in 2024, North America spends nearly USD 4 billion on polycystic ovarian syndrome and related diseases. In addition, menstrual irregularities were seen in 22.8% of patients. According to the Alberta Women’s Health Foundation report published in February 2023, states that nearly 1.4 million women in Canada may be affected by PCOS. The companies are engaged in research to discover new treatment alternatives and reduce increased prevalence of PCOS. The key players involved in the market include Abbott, Bristol Myers Squibb Company, and Pfizer, Inc.

U.S. Polycystic Ovarian Syndrome Treatment Trends

The U.S. polycystic ovarian syndrome treatmentmarket accounted for an 88.5% share of the North America market in 2024. According to the Endocrine Society report published in January 2022, nearly 5 to 6 million women in U.S. are affected with PCOS. Companies are involved in innovating treatment alternatives such as innovative controlled ovarian stimulation (COS) which was developed in 2021 to treat PCOS. The UCSF PCOS clinic is developed to focus on creating an integrated approach to treat polycystic ovarian syndrome. Key players such as Abbott, Pfizer, Inc., and Bristol Myers Squibb Company are involved in driving the market growth.

Europe Polycystic Ovarian Syndrome Treatment Market Trends

Europe accounted for a significant market share in 2024 in the polycystic ovarian syndrome treatment market. According to the report published by The Lancet in October 2022, polycystic ovarian syndrome cases are recorded at approximately 276.4 cases per 100,000 people in the European region. The European Union (EU) is taking initiatives such as SPIOMET4Health to provide treatment for the syndrome in September 2022. Many organizations are participating in this EU project, such as Make Mothers Matter (MMM) organization. Such initiatives are expected to drive market growth.

The polycystic ovarian syndrome treatment market in the UK is growing due to the fact that one in five women is affected by polycystic ovarian syndrome, according to the London Women’s Centre organization. The NHS England is joining forces with the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA) through the Accelerated Access Collaboration to set a pace for accessing technologies proven safe and effective for the patients. For instance, women with PCOS condition are likely to develop metabolic syndrome, which may lead to diabetes; the NHS Diabetes Prevention programme is established to identify patients at high risk of developing the chronic diseases and refer them to a 9-month lifestyle change programme. Such initiatives are expected to drive market growth in the region.

Asia Pacific Polycystic Ovarian Syndrome Treatment Market Trends

Asia Pacific’s polycystic ovarian syndrome treatment market is estimated to register the fastest CAGR over the forecast period. Polycystic ovarian condition affects nearly 25% of women in Australia, according to The Endocrine Society of Australia. The Australian government is taking initiatives such as forming international guideline in August 2023 to improve the PCOS condition among women, as it is the leading cause of infertility. This guideline is led by the Monash Centre for Health Research and Implementation (MCHRI) at Monash University based in Australia.

China polycystic ovarian syndrome treatment market is estimated to register the significant growth over the forecast period According to the AME report published in January 2021; polycystic ovarian syndrome is increasing in Chinese women; the polycystic ovarian syndrome is increasing in Chinese women. As study published by ScienceDirect in September 2023, verified the efficacy and safety of Chinese patented medicine Xiao Yao San (XYS) to treat PCOS, and results showed that XYS combined with conventional medicines can improve ovulation and fertility rates.

The polycystic ovarian syndrome treatment market in India is estimated to register the significant growth over the forecast period. The rising prevalence of the condition in India is the major driving factor for the region’s market growth. According to the Press Information Bureau (PIB) of the Indian government, a report published in January 2023, the PCOS cases in the nation range from 3.7 - 22.5% and are the major cause of female infertility, estimated 64%. To address this issue, the Indian Council of Medical Research (ICMR), initiated a multicentric study nationwide in 2021. Some medical drugs available in the country to treat PCOS are Follical Forte Tablets, PCOS Care Capsules, Ferjoy-IN Tablets to treat hormonal imbalances, and Cureveda Women Elixir to provide relief from the symptoms. Such increasing incidences, initiatives, and companies innovating new drugs are driving the market growth.

Latin America Polycystic Ovarian Syndrome Treatment Market Trends

The PCOS treatment market in Latin America is experiencing steady growth, driven by increasing awareness and the rising prevalence of the condition among women of reproductive age. While specific prevalence rates vary across countries, studies indicate a significant burden of PCOS in the region, necessitating enhanced diagnostic and treatment approaches. The Latin American Association of Gynecological Endocrinology has emphasized the need for evidence-based practices tailored to the regional context, highlighting challenges such as cost and accessibility of treatments.

MEA Polycystic Ovarian Syndrome Treatment Market Trends

In the Middle East and Africa, the PCOS treatment market is witnessing significant growth, propelled by a high prevalence of the condition and increasing investments in healthcare infrastructure. Studies have reported a substantial burden of PCOS in the Middle East and North Africa (MENA) region, with variations in prevalence influenced by factors such as age and sociodemographic index. In the United Arab Emirates, research conducted at Latifa Women and Children's Hospital in Dubai has highlighted the need for enhanced diagnostic criteria and awareness campaigns to address the underdiagnosis of PCOS.

Key Polycystic Ovarian Syndrome Treatment Company Insights

Some key companies in polycystic ovarian syndrome treatment include, - AstraZeneca, Bayer AG, Merck KGaA, Pfizer, Inc, Teva Pharmaceutical Industries Ltd, Abbott. Key companies are involved in taking strategic initiatives such as in innovating new products, collaborating with institutions and other industries and establishing partnerships.

• Bayer AG is a global life science company with core competencies in healthcare. The company manufactures medicinal products such as aspirin, antibiotics, anti-infectives, and cardiovascular and oncology medications. Bayer AG is involved in forming strategic initiatives and collaborations to innovate medication to treat PCOS.

• Teva Pharmaceutical Industries Ltd is an Israel based pharmaceutical company specializing in generic drugs, active pharmaceutical ingredients and contract manufacturing services. The company has an array of drugs such as Ovaleap, and Seasonique to treat fertility, and related disorders.

Recent Developments

• In April 2023, Celmatix Inc., a women's health biotech company, announced the launch of a novel drug program targeting melatonin receptors outside the central nervous system (CNS) to treat PCOS. This initiative aims to address the root causes of PCOS by restoring ovarian function, rather than merely managing symptoms. The program focuses on developing a melatonin receptor agonist with peripherally-preferred pharmacokinetics, enhancing therapeutic action at target tissues like the ovary while minimizing CNS-related side effects such as drowsiness.

• In August 2023, BioSyent Inc. announced the Canadian launch of Inofolic, a natural health product designed for women living with PCOS. Inofolic combines myo-inositol and folic acid in a unique soft-gel capsule, aiming to support women with PCOS by addressing various symptoms associated with the condition. This product offers a new option for the approximately 1.4 million Canadian women affected by PCOS.

• In January 2022, Evotec-partnered biotechnology company Celmatix Inc. announced its third milestone for the PCOS drug program in its five-year multi-target alliance.

• In December 2021, Organon Group, a global women’s healthcare company, acquired Forendo Pharma to expand its pipeline of products targeting endometriosis and polycystic ovarian syndrome (PCOS).

Polycystic Ovarian Syndrome Treatment Market Report Scope

Global Polycystic Ovarian Syndrome Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polycystic ovarian syndrome treatment market report based on drug Class, surgery, distribution channel, and region.

• Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)

  • Oral Contraceptives

  • Antiandrogens

  • Insulin-sensitizing Agent

  • Antidepressant

  • Anti-obesity

• Surgery Outlook (Revenue, USD Billion, 2018 - 2030)

  • Ovarian Wedge Resection

  • Laparoscopic Ovarian Drilling

• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospital Pharmacy

  • Drug Store & Retail Pharmacy

  • Online Providers

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

  • Middle East and Africa (MEA)

    • KSA

    • UAE

    • South Africa